Punto di riferimento in allergologica


> if have you not a user and password contact us

Lofarma leads the process: fullfillment of Therapeutic Allergen Directive in Germany

Since more than 5 years now Lofarma Deutschland GmbH is representing the German subsidiary of Lofarma SpA, one of the leaders in allergy immunotherapy in Italy. >>>

Lofarma Biotechnology to fight Ragweed allergy

Lofarma has developed a unique biotechnology to improve the safety profile and bioavailability of Allergen Immunotherapy (AIT) for Ragweed. The treatment is based on a specific chemical modification by which native allergens are modified into monomeric allergoids, adopted for the Monomeric Allergoid Immunotherapy (MAIT). >>>